REN and hydrops fetalis: After a mean follow-up of 4.2 years, the intervention group received more renin–angiotensin–aldosterone system (RAAS) therapy (56.5% vs. 49.6%; p = 0.01) and overall was associated with a lower incidence of asymptomatic LV dysfunction with or without new HF diagnosis (5.3% vs. 8.7%, OR 0.55, 95% CI 0.37–0.82; p = 0.003).